Dr Reddys Laboratories (RDY) Revenue (2009 - 2023)

Dr Reddys Laboratories (RDY) posted quarterly Revenue of $828.0 million for Q2 2023, up 2.1% quarter-over-quarter from $811.0 million in Q1 2023.

Dr Reddys Laboratories (RDY) Revenue (2009 - 2023) Analysis & Trends

Dr Reddys Laboratories' Revenue history runs 15 years deep, the most recent figure standing at $828.0 million for Q2 2023.

In Q2 2023, Revenue changed N/A year-over-year to $828.0 million; the TTM figure through Jun 2023 stood at $824002.4 billion (changed N/A YoY), while the FY2026 annual figure was $3.6 billion, down 6.06% from the prior year.
Revenue for Q2 2023 stood at $828.0 million, up from $811.0 million in the prior quarter.
The five-year high for Revenue was $824000.0 billion in Q3 2022, with the low at $544.0 million in Q1 2019.
The 5-year median for Revenue is $674.0 million (2019), against an average of $68667.3 billion.
The sharpest annual moves came in 2019 and 2020: Revenue rose 28.44% in 2019, then fell 0.3% in 2020.
Dr Reddys Laboratories' Revenue stood at $614.0 million in 2019, then advanced by 9.93% to $675.0 million in 2020, then grew by 15.11% to $777.0 million in 2021, then fell by 1.29% to $767.0 million in 2022, then gained by 7.95% to $828.0 million in 2023.
Business Quant data shows RDY's Revenue at $828.0 million in Q2 2023, $811.0 million in Q1 2023, and $767.0 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Haleon	43.76 Bn	42.79 Bn	-	-
2	Teva Pharmaceutical Industries	43.38 Bn	39.73 Bn	2.15 Bn	4.14 Bn
3	Zoetis	31.61 Bn	29.93 Bn	1.05 Bn	2.47 Bn
4	Takeda Pharmaceutical	28.64 Bn	22.84 Bn	5.10 Bn	7.65 Bn
5	United Therapeutics	22.20 Bn	19.54 Bn	683.80 Mn	783.30 Mn
6	Viatris	18.82 Bn	17.93 Bn	1.46 Bn	3.76 Bn
7	Neurocrine Biosciences	15.67 Bn	15.28 Bn	935.80 Mn	959.00 Mn
8	Elanco Animal Health	12.11 Bn	11.58 Bn	798.00 Mn	1.37 Bn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	-
10	Alkermes	8.21 Bn	7.55 Bn	397.90 Mn	496.01 Mn

Download Data